Osteoclastogenesis in abdominal aortic aneurysms: A new therapeutic target

AD Leung, D Yamanouchi - Current Drug Targets, 2018 - ingentaconnect.com
Abdominal aortic aneurysms (AAA) are a major cause of death. Currently, the mainstay of
treatment for AAA is surgical repair and there are no FDA approved medical therapies for …
被引用次数：2 相关文章

Osteoclastogenesis in Abdominal Aortic Aneurysms: A New Therapeutic Target

AD Leung, D Yamanouchi - Current drug targets, 2018 - pubmed.ncbi.nlm.nih.gov
Abdominal aortic aneurysms (AAA) are a major cause of death. Currently, the mainstay of
treatment for AAA is surgical repair and there are no FDA approved medical therapies for …

Osteoclastogenesis in abdominal aortic aneurysms: A new therapeutic target

AD Leung, D Yamanouchi - Current Drug Targets, 2018 - pure.fujita-hu.ac.jp
抄録 Abdominal aortic aneurysms (AAA) are a major cause of death. Currently, the mainstay
of treatment for AAA is surgical repair and there are no FDA approved medical therapies for …

Osteoclastogenesis in Abdominal Aortic Aneurysms: A New Therapeutic Target.

AD Leung, D Yamanouchi - Current Drug Targets, 2018 - europepmc.org
Abdominal aortic aneurysms (AAA) are a major cause of death. Currently, the mainstay of
treatment for AAA is surgical repair and there are no FDA approved medical therapies for …

Osteoclastogenesis in abdominal aortic aneurysms: A new therapeutic target

AD Leung, D Yamanouchi - Current Drug Targets, 2018 - pure.fujita-hu.ac.jp
Abdominal aortic aneurysms (AAA) are a major cause of death. Currently, the mainstay of
treatment for AAA is surgical repair and there are no FDA approved medical therapies for …